Multiple myeloma is the second most common type of blood cancer, with approximately 450 new cases diagnosed annually in Norway

By HEOR Staff Writer

March 29, 2023

A health technology assessment (HTA) of treatment regimens for patients with multiple myeloma in Norway was done. The goals of treatment are to prolong life, achieve a strong response without side effects, and maintain quality of life.

The article discusses the uncertainty surrounding the results of a health economic analysis of treatment regimens for multiple myeloma. The uncertainty is due to reliance on component network meta-analysis and lack of access to patient level data. The methods used to derive underlying survival curves may overestimate treatment costs due to inaccurate accounting for dose reductions during treatment.

The difficulty in drawing clear conclusions about the most effective treatment regimen for patients with refractory or relapsed multiple myeloma is clear. The six triplet combinations mentioned have favourable hazard ratios for overall survival, but there is substantial uncertainty in the evidence. Cost-effectiveness results are also uncertain and need to be viewed in the context of each reference group. Only seven treatments were not dominated by others. Patients with RRMM may lose 12-15 healthy life-years, and there is a high degree of uncertainty in the cost-effectiveness results.

Reference url

Recent Posts

AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health

By João L. Carapinha

October 28, 2025

A BMJ article explores the potential for AI chatbot delusions to validate or induce delusional thinking. Emerging evidence shows that individuals with and without previous psychiatric histories have reported distressing delusions after extensive chatbot interactions. It remains uncertain if AI di...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex Dynamics

By João L. Carapinha

October 27, 2025

Pharmaceutical innovation funding in the UK faces scrutiny amid industry claims that low NHS spending deters investments, but this narrative overlooks key drivers like scientific talent, tax incentives, and operational efficiencies rather than drug prices alone. A recent Lancet article critiques ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access

By HEOR Staff Writer

October 24, 2025

Darolutamide prostate cancer treatment has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which issued final draft guidance recommending darolutamide combined with androgen deprivation therapy (ADT) for adults with hormone-sensitive metastatic pros...